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OBJECTIVE: This study was designed to 1) measure adherence
to inhaled corticosteroid (ICS) therapy using both prescription
claims and a patient survey; 2) identify local adverse events
(LAEs) from the patient perspective and from reports in the
medical chart; and 3) evaluate the association between LAEs
and adherence to ICS therapy. METHODS: Patients aged 6–64
years with persistent asthma, deﬁned using an established algo-
rithm, and at least 2 ICS prescriptions were selected from a
claims database (1999–2005) of a central Massachusetts
medical group practice organization. Prescription claims were
used to calculate the ICS medication possession ratio (MPR) as
the sum of ICS medication days supply over the year after
index medication divided by 365. A survey obtained informa-
tion on patient-reported adherence to ICS therapy by using the
Morisky scale and assessed patient-reported LAEs using the
validated Inhaled Corticosteroid Questionnaire (ICQ). Medical
charts of survey respondents were abstracted for LAEs.
RESULTS: The study sample included 372 survey respondents.
Only 2.7% met the claims-based measure of good adherence (a
MPR  80%). Patient-reported adherence was much higher;
20.7% of patients were highly adherent based on Morisky scale
(score = 0). Medical chart review identiﬁed 27.2% of patients
with at least one LAE within a year after ICS index date, but
only in 5.6% of patients were LAEs related to ICS use.
However, the responses to the ICQ showed that 47% of
patients reported being bothered at least “quite a lot” by at
least one LAE. Multivariate analyses indicated that unpleasant
taste was signiﬁcantly related to lower adherence based on the
Morisky scale (P = 0.0175). CONCLUSION: Patient-reported
adherence was higher than claims-based. Patients reported
being bothered by LAEs more often than recorded in medical
charts. Unpleasant taste appears to be associated with lower
adherence based on the Morisky scale.
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OBJECTIVE: Chronic obstructive pulmonary disease (COPD)
is a major burden to patients, caregivers, and physicians. The
purpose of this focus group research was to identify and describe
patients’ and caregivers’ perceptions on abilities to perform daily
living activities, satisfaction with COPD management, and eco-
nomic burden of the disease. Also, focus groups of physicians
elicited similar information. METHODS: Focus groups of
patient/caregiver pairs, patients, caregivers, primary care physi-
cians (PCPs) and pulmonologists were conducted in two states.
Patients recruited had a live-in caregiver and had been diagnosed
with COPD for 1 year, caregivers attended to their patients for
1 year, and PCPs and pulmonologists saw at least 10 COPD
patients per week. Focus groups were 90–120 minutes and were
conducted by trained focus group moderators. RESULTS:
Seventeen patients, 17 caregivers, 12 PCPs, and 8 pulmonologists
participated in the focus groups. COPD patients in New Jersey
(NJ) reported receiving better care, seeing specialists more often,
and having better access to pulmonary rehabilitation than
patients in Florida (FL). Only one-third of FL patients had a
spirometry test during their last physician visit, compared to half
of NJ patients. Patients treated by PCPs reported having inad-
equate appointment time and feeling like a burden to their phy-
sician. Patients and caregivers described difﬁculties in the daily
lives of patients including social interactions, household chores,
and bathing. Economic burden identiﬁed included inability to
work and high co-pays. PCPs reported that depression and
anxiety are commonly observed in COPD patients. Awareness of
COPD treatment guidelines was greater among pulmonologists
than PCPs. CONCLUSION: Patient and caregiver perceptions of
COPD care demonstrate the need for improvement in the man-
agement of COPD. Medical care differences among physicians
suggest a need for better dissemination of treatment guidelines. A
national survey will generate quantitative ﬁndings regarding the
evolving treatment of COPD.
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OBJECTIVE: Automated IVR telephone-based systems are
widely used in many aspects of clinical trials, but there is
relatively little empirical data to support the use of IVR for
collecting patient reported outcomes (PROs) such as daily
symptom diaries. We have evaluated IVR in a placebo-
controlled study of seasonal rhinitis. METHODS: Patients were
allocated at random to receive either 200ìg budesonide or
placebo for three weeks. All patients received up to 120 mg per
day terfenadine as required. Patients dialled into an IVR system
each evening. Blocked nose, stuffy nose, runny nose, and eye
symptoms were rated by pressing a button on the phone
keypad to record severity on the scale 0 = absent; 1 = mild;
2 = moderate; 3 = severe. Patients also recorded the number of
terfenadine tablets taken. RESULTS: Data were collected from
32 patients (15 male) aged 19–65 years. Patients were able to
use the IVR system without difﬁculty. All four symptoms
showed lower average severity over the study period for the
budesonide group than for placebo. This was signiﬁcant for
blocked nose (Wilcoxon S = 237, p < 0.01); eye symptoms
(S = 218; p < 0.05); overall symptoms (S = 229, p < 0.05). The
number of terfenadine tablets taken was also lower in the
budesonide group than for placebo (S = 225, p < 0.05). CON-
CLUSION: These data demonstrate the effects of an established
treatment, and thus suggest that IVR is a valid method for
collecting PRO data in an unsupervised environment. The
application was relatively simple, involving familiar and easily
understood symptoms, and response options that were the
same for all symptoms. Further research to investigate more
complex PRO applications is warranted.
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